Associate Director, FP&A

vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, a potential first-in-class oral glucokinase activator being investigated in a U.S. Phase 3 study for the treatment of T1D. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases.

Learn more at  or follow the company on Linked In.

The Associate Director, FP&A is vTv’s senior financial planning leader below the CFO and owns the forecasting, budgeting and analysis that shape how the company allocates capital across its clinical development programs. The work is directly connected to patients: the decisions this role informs determine how quickly vTv can advance potential treatments for people living with type 1 diabetes.

vTv is a small, fully remote organization advancing a Phase 3 asset. This is a hands-on role and the person in this seat builds and owns the models personally rather than managing a team that builds them, and partners day to day with Clinical Operations, R&D, Accounting and G&A.

• Own the annual budget, quarterly reforecast and long-range plan, including the consolidated operating expense, headcount and cash flow models.
• Maintain the cash runway and burn rate models that underpin the company’s internal planning and its external funding disclosures, including scenario and sensitivity analysis tied to clinical timelines.
• Partner with Clinical Operations to translate enrollment, site activation, CRO contract and change order assumptions into forecast program spend and cash outflow.
• Support headcount and personnel cost planning, including stock-based compensation inputs, in partnership with HR and Accounting.

• Serve as the dedicated FP&A partner to program teams and functional leaders, embedding financial insight into how the business plans, operates and makes decisions day to day.
• Evaluate strategic opportunities and investment tradeoffs, challenge assumptions and support disciplined decision-making on resource allocation and portfolio priorities.
• Identify emerging financial risks and opportunities early, raise them proactively and propose practical solutions.
• Translate complex analyses into clear, actionable recommendations for audiences without a finance background.

• Prepare monthly, quarterly and annual reporting packages and executive narratives for the CFO, senior leadership and the Board of Directors, including budget-to-actual variance analysis with clear explanation of drivers.
• Support the accounting close in partnership with Accounting, with particular attention to clinical trial and other R&D accruals.
• Provide analysis and supporting schedules for external reporting, including inputs to quarterly and annual SEC filings and earnings materials, coordinating with Accounting, Legal and Investor Relations.
• Maintain rigorous data accuracy and consistency across financial models, source systems and reporting.

• Advance vTv’s financial planning systems, reporting and analytics, including evaluation and implementation of planning or clinical trial financial management tools where the business case supports the investment.
• Champion the adoption of AI and automation across FP&A to streamline recurring workflows, reduce manual effort and free capacity for higher-value analysis.
• Document and strengthen planning and reporting processes so they scale as the company moves toward potential registration and launch.

• BS/BA in Finance, Accounting, Economics or a related field.
• 10+ years of progressive FP&A or corporate finance experience, including at least five years supporting biotech or pharmaceutical R&D.
• Advanced financial modeling in Excel, with demonstrated ownership of an operating expense and cash forecast model from build through board-level presentation.
• Working knowledge of US GAAP, forecasting methodologies, clinical program accruals and R&D expense recognition.
• Experience supporting a public company reporting cycle, including quarterly close, SEC filing inputs and board reporting.
• Proven track record of cross-functional influence and executive-level communication.
• Comfort operating with ambiguity and limited infrastructure in a small, fully remote…